Votrient
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Pazopanib is noninferior to sunitinib with respect to progression-free survival (PFS) for the treatment of metastatic renal cell…
Earlier today the FDA approved pazopanib (Votrient) to treat patients with advanced soft-tissue sarcoma who have previously…
----------------------------INDICATIONS AND USAGE--------------------VOTRIENT is a kinase inhibitor indicated for the treatment…